CN1924014A - 抑制肿瘤转移的特异性干扰MTA1 mRNA的干扰RNA序列 - Google Patents
抑制肿瘤转移的特异性干扰MTA1 mRNA的干扰RNA序列 Download PDFInfo
- Publication number
- CN1924014A CN1924014A CNA2005100936987A CN200510093698A CN1924014A CN 1924014 A CN1924014 A CN 1924014A CN A2005100936987 A CNA2005100936987 A CN A2005100936987A CN 200510093698 A CN200510093698 A CN 200510093698A CN 1924014 A CN1924014 A CN 1924014A
- Authority
- CN
- China
- Prior art keywords
- mta1
- cell
- sirna
- interference
- transfection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001027925 Homo sapiens Metastasis-associated protein MTA1 Proteins 0.000 title claims abstract description 25
- 102100037517 Metastasis-associated protein MTA1 Human genes 0.000 title claims abstract description 25
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title claims description 26
- 206010027476 Metastases Diseases 0.000 title claims description 14
- 230000009401 metastasis Effects 0.000 title description 7
- 230000002401 inhibitory effect Effects 0.000 title description 5
- 239000013612 plasmid Substances 0.000 claims description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 11
- 101100129408 Neurospora crassa mta-1 gene Proteins 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 118
- 238000001890 transfection Methods 0.000 description 75
- 210000004881 tumor cell Anatomy 0.000 description 27
- 210000004072 lung Anatomy 0.000 description 24
- 238000012546 transfer Methods 0.000 description 16
- 238000000137 annealing Methods 0.000 description 12
- 101150096007 MTA1 gene Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 230000035876 healing Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- -1 poly-carbon ester Chemical class 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108010033040 Histones Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 239000012097 Lipofectamine 2000 Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100238751 Mus musculus Mta1 gene Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000037440 gene silencing effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000002629 repopulating effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
实验处理组 | 肿瘤体积(mm3) | 肿瘤重量(g) | 成瘤率(%) | 瘤重抑制率(%) |
ControlPsilencer3.1-MTA1-siRNA | 9052.97±3743.85416.59±274.15 | 9.67±2.700.41±0.22 | 6/6(100)4/6(66.7) | 095.75 |
实验处理组(%) | 肺重量(g) | 肺结节数(个) | 肺结节抑制率 |
ControlPsilencer3.1-MTA1-siRNA | 1.08±0.320.51±0.05 | 64.6±27.2510.8±11.88 | 083.28 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100936987A CN1924014B (zh) | 2005-09-01 | 2005-09-01 | 抑制肿瘤转移的特异性干扰MTA1 mRNA的干扰RNA序列 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100936987A CN1924014B (zh) | 2005-09-01 | 2005-09-01 | 抑制肿瘤转移的特异性干扰MTA1 mRNA的干扰RNA序列 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1924014A true CN1924014A (zh) | 2007-03-07 |
CN1924014B CN1924014B (zh) | 2011-08-17 |
Family
ID=37816839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100936987A Expired - Fee Related CN1924014B (zh) | 2005-09-01 | 2005-09-01 | 抑制肿瘤转移的特异性干扰MTA1 mRNA的干扰RNA序列 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1924014B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103421738A (zh) * | 2012-05-18 | 2013-12-04 | 中国医学科学院肿瘤研究所 | Mta1及其抑制剂的制药用途 |
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
CN107988254A (zh) * | 2017-10-18 | 2018-05-04 | 广东医科大学 | 一种mta1基因表达载体的构建与鉴定方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ289155B6 (cs) * | 1993-12-29 | 2001-11-14 | The Regents Of The University Of California | Izolovaný polynukleotid, který kóduje methylthioadenosin fosforylázu, expresní vektor a protilátka |
US20050176072A1 (en) * | 2002-06-21 | 2005-08-11 | Martin Michelle D. | MTA1 is a predictive and prognostic factor in human breast cancer |
-
2005
- 2005-09-01 CN CN2005100936987A patent/CN1924014B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103421738A (zh) * | 2012-05-18 | 2013-12-04 | 中国医学科学院肿瘤研究所 | Mta1及其抑制剂的制药用途 |
CN103421738B (zh) * | 2012-05-18 | 2018-01-23 | 中国医学科学院肿瘤医院 | Mta1及其抑制剂的制药用途 |
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
CN107988254A (zh) * | 2017-10-18 | 2018-05-04 | 广东医科大学 | 一种mta1基因表达载体的构建与鉴定方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1924014B (zh) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene | |
Pallante et al. | MicroRNA deregulation in human thyroid papillary carcinomas | |
Tsai et al. | MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma | |
CN101316935B (zh) | 一种用于诊断食道癌的芯片 | |
CN109182542B (zh) | 一种与鸡屠体性状相关的snp分子标记及其应用 | |
CN102453713B (zh) | HULC siRNA及其在制备治疗肝癌的药物中的用途 | |
Pasdar et al. | Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents | |
CN108504658B (zh) | Linc01836在制备胃癌诊断产品、治疗药物中的用途 | |
Kim et al. | Translational control of FOG-2 expression in cardiomyocytes by microRNA-130a | |
CN105056250B (zh) | 一种microRNA在制备治疗前列腺癌的药物中的应用 | |
CN1924014A (zh) | 抑制肿瘤转移的特异性干扰MTA1 mRNA的干扰RNA序列 | |
CN103947614B (zh) | 一种抑制家蚕体内BmNPV病毒增殖的方法 | |
CN105861551A (zh) | 联合表达microRNAs抑制乳腺癌细胞增殖的载体及其构建方法和应用 | |
CN102876716B (zh) | 特异促进肝细胞cyp2e1基因高表达的慢病毒表达载体及其构建方法与应用 | |
Zhang et al. | Proteome atlas of human chromosome 8 and its multiple 8p deficiencies in tumorigenesis of the stomach, colon, and liver | |
CN105907757B (zh) | Linc00052基因的用途及其相关药物 | |
CN102102102A (zh) | hsa-miR-185的新用途 | |
CN101353656A (zh) | 抑制表皮生长因子受体基因表达的siRNA及其应用 | |
CN110295169A (zh) | 一种miRNA及其用于杀灭褐飞虱的应用 | |
CN104357451B (zh) | 针对dd3基因的小干扰rna及其表达载体构建与应用 | |
CN106191118A (zh) | 一种慢病毒干扰载体及其构建方法和应用 | |
CN1247608C (zh) | 一种新型乳腺癌基因治疗药物hdm2-siRNA | |
CN1800387A (zh) | 抑制多效生长因子基因表达的小干扰rna及其应用 | |
Xu et al. | Evaluation of novel SNPs and haplotypes within the ATBF1 gene and their effects on economically important production traits in cattle | |
CN101787368B (zh) | 抑制人Z38基因表达的siRNA及其在制备抗乳腺肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TUMOR HOSPITAL, CHINESE MEDICAL ACADEMY Free format text: FORMER OWNER: TUMOUR INST., CHINA MEDICAL SCIENCE RESEARCH ACADEMY Effective date: 20150804 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150804 Address after: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee after: Tumor Hospital, Chinese Medical Academy Address before: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee before: Tumour Inst., China Medical Science Research Academy |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110817 Termination date: 20170901 |
|
CF01 | Termination of patent right due to non-payment of annual fee |